Alan R. Shuldiner

94.6k total citations · 7 hit papers
363 papers, 19.8k citations indexed

About

Alan R. Shuldiner is a scholar working on Molecular Biology, Genetics and Physiology. According to data from OpenAlex, Alan R. Shuldiner has authored 363 papers receiving a total of 19.8k indexed citations (citations by other indexed papers that have themselves been cited), including 150 papers in Molecular Biology, 105 papers in Genetics and 81 papers in Physiology. Recurrent topics in Alan R. Shuldiner's work include Adipose Tissue and Metabolism (61 papers), Pancreatic function and diabetes (49 papers) and Metabolism, Diabetes, and Cancer (41 papers). Alan R. Shuldiner is often cited by papers focused on Adipose Tissue and Metabolism (61 papers), Pancreatic function and diabetes (49 papers) and Metabolism, Diabetes, and Cancer (41 papers). Alan R. Shuldiner collaborates with scholars based in United States, Israel and France. Alan R. Shuldiner's co-authors include Braxton D. Mitchell, Toni I. Pollin, Kristi D. Silver, Da‐Wei Gong, Francesco S. Celi, John C. McLenithan, Jesse Roth, Coleen Damcott, Rongze Yang and William C. Knowler and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Alan R. Shuldiner

356 papers receiving 19.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy

2009 1.1k citations Alan R. Shuldiner profile →
Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action

2006 715 citations Alan R. Shuldiner, John C. McLenithan et al. profile →
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

2013 680 citations Julie A. Johnson, Alan R. Shuldiner et al. profile →
TCF7L2 Polymorphisms and Progression to Diabetes in the Diabetes Prevention Program

2006 627 citations Toni I. Pollin, Alan R. Shuldiner et al. profile →
Omentin Plasma Levels and Gene Expression Are Decreased in Obesity

2007 617 citations Alan R. Shuldiner, Toni I. Pollin et al. profile →
A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection

2008 517 citations Toni I. Pollin, Coleen Damcott et al. Science profile →
Genetic Variation in the β₃-Adrenergic Receptor and an Increased Capacity to Gain Weight in Patients with Morbid Obesity

1995 501 citations Alan R. Shuldiner et al. profile →

Peers

Countries citing papers authored by Alan R. Shuldiner

Since Specialization

Citations

This map shows the geographic impact of Alan R. Shuldiner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan R. Shuldiner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan R. Shuldiner more than expected).

Fields of papers citing papers by Alan R. Shuldiner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan R. Shuldiner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan R. Shuldiner. The network helps show where Alan R. Shuldiner may publish in the future.

Co-authorship network of co-authors of Alan R. Shuldiner

This figure shows the co-authorship network connecting the top 25 collaborators of Alan R. Shuldiner. A scholar is included among the top collaborators of Alan R. Shuldiner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan R. Shuldiner. Alan R. Shuldiner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Acute pharmacodynamic responses to sitagliptin: Drug‐induced increase in early insulin secretion in oral glucose tolerance test 2024 ·Clinical and Translational Science ·Amber L. Beitelshees, Elizabeth A. Streeten, (unknown), Hilary B. Whitlatch, Braxton D. Mitchell, Alan R. Shuldiner, May E. Montasser, Simeon I. Taylor	1
2	Transcriptional profiling in microglia across physiological and pathological states identifies a transcriptional module associated with neurodegeneration 2024 ·Communications Biology ·(unknown), Neelroop Parikshak, Daria Zamolodchikov, Sahar Gelfman, Arden Moscati, Lee Dobbyn, Eli A. Stahl, Alan R. Shuldiner, Giovanni Coppola	8
3	Two founder variants account for over 90% of pathogenic BRCA alleles in the Orkney and Shetland Isles in Scotland 2024 ·European Journal of Human Genetics ·Shona M. Kerr, Lucija Klarić, (unknown), (unknown), (unknown), Gannie Tzoneva, Alan R. Shuldiner, Zosia Miedzybrodzka, James F. Wilson	1
4	Massive Parallel DNA Sequencing of Patients with Inherited Cardiomyopathies in Cyprus and Suggestion of Digenic or Oligogenic Inheritance 2024 ·Genes ·(unknown), Marios Ioannides, Christiana Polydorou, Gregory Papagregoriou, Apostolos Malatras, (unknown), (unknown), (unknown), (unknown), Christos Eftychiou, (unknown), Theodoros Christophides, Anna Alkelai, Manav Kapoor, Alan R. Shuldiner, Panayiotis Avraamides, Constantinos Deltas	0
5	Pharmacogenetics of sodium‐glucose co‐transporter‐2 inhibitors: Validation of a sex‐agnostic pharmacodynamic biomarker 2023 ·Diabetes Obesity and Metabolism ·Simeon I. Taylor, (unknown), (unknown), May E. Montasser, Hilary B. Whitlatch, Braxton D. Mitchell, Alan R. Shuldiner, Elizabeth A. Streeten, Amber L. Beitelshees	3
6	In-Depth Mass Spectrometry Analysis Reveals the Plasma Proteomic and N-Glycoproteomic Impact of an Amish-Enriched Cardioprotective Variant in B4GALT1 2023 ·Molecular & Cellular Proteomics ·(unknown), Shruti Nayak, (unknown), Lili Guo, Giusy Della Gatta, (unknown), Gábor Halász, May E. Montasser, Alan R. Shuldiner, Yuan Mao, Ning Li	5
7	Glucocorticoid Receptor Gene (NR3C1) Polymorphisms and Metabolic Syndrome: Insights from the Mennonite Population 2023 ·Genes ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jennifer E. Hundt, Alan R. Shuldiner, Fabiana L. Lopes, (unknown), André Franke, Luís Felipe Ribeiro Pinto, Sheila Coelho Soares‐Lima, (unknown), Angelica Beate Winter Boldt	5
8	Genome-wide significant risk loci for mood disorders in the Old Order Amish founder population 2023 ·Molecular Psychiatry ·Elizabeth Humphries, Kwangmi Ahn, Rachel L. Kember, Fabiana L. Lopes, Evelina Mocci, Juan M. Peralta, John Blangero, David C. Glahn, Fernando S. Goes, Peter P. Zandi, Peter Kochunov, Cristopher V. Van Hout, Alan R. Shuldiner, Toni I. Pollin, Braxton D. Mitchell, Maja Bućan, L. Elliot Hong, Francis J. McMahon, Seth A. Ament	1
9	Clinical case study meets population cohort: identification of a BRCA1 pathogenic founder variant in Orcadians 2023 ·European Journal of Human Genetics ·Shona M. Kerr, (unknown), Lucija Klarić, Christine Bell, Dawn O’Sullivan, David Buchanan, Joseph J. Grzymski, Cristopher V. Van Hout, Gannie Tzoneva, Alan R. Shuldiner, James F. Wilson, Zosia Miedzybrodzka	3
10	An Amish founder population reveals rare-population genetic determinants of the human lipidome 2022 ·Communications Biology ·May E. Montasser, Stella Aslibekyan, Vinodh Srinivasasainagendra, Hemant K. Tiwari, Amit Patki, Minoo Bagheri, Tobias Kind, Dinesh Kumar Barupal, Sili Fan, James A. Perry, Kathleen A. Ryan, Alan R. Shuldiner, Donna K. Arnett, Amber L. Beitelshees, Marguerite R. Irvin, Jeffrey R. O’Connell	7
11	Multiple dimensions of stress vs. genetic effects on depression 2021 ·Translational Psychiatry ·Mark D. Kvarta, Heather Bruce, Joshua Chiappelli, Stephanie Hare, Eric L. Goldwaser, Jessica Sewell, Hemalatha Sampath, (unknown), (unknown), Kathryn S. Hatch, Elizabeth Humphries, Seth A. Ament, Alan R. Shuldiner, Braxton D. Mitchell, Francis J. McMahon, Peter Kochunov, L. Elliot Hong	4
12	Heterozygosity for a Pathogenic Variant in SLC12A3 That Causes Autosomal Recessive Gitelman Syndrome Is Associated with Lower Serum Potassium 2021 ·Journal of the American Society of Nephrology ·Xuesi Wan, James A. Perry, Haichen Zhang, (unknown), Kathleen A. Ryan, Cristopher V. Van Hout, Jeffrey G. Reid, John D. Overton, Aris Baras, Zhe Han, Elizabeth A. Streeten, Yanbing Li, Braxton D. Mitchell, Alan R. Shuldiner, Mao Fu	11
13	Similar burden of pathogenic coding variants in exceptionally long‐lived individuals and individuals without exceptional longevity 2020 ·Aging Cell ·(unknown), Gabriel Lidzbarsky, Sofiya Milman, Tina Gao, Patrick Sin‐Chan, Claudia Gonzaga‐Jauregui, Joris Deelen, Alan R. Shuldiner, Nir Barzilai, Gil Atzmon	7
14	Genome-wide association analysis of common genetic variants of resistant hypertension 2018 ·The Pharmacogenomics Journal ·(unknown), Nihal El Rouby, Caitrin W. McDonough, Yan Gong, Leslie A. McClure, Braxton D. Mitchell, Richard B. Horenstein, Robert L. Talbert, Dana C. Crawford, Matthew A. Gitzendanner, Atsushi Takahashi, Toshihiro Tanaka, Michiaki Kubo, Carl J. Pepine, Rhonda M. Cooper‐DeHoff, Oscar Benavente, Alan R. Shuldiner, Julie A. Johnson	16
15	The GH receptor exon 3 deletion is a marker of male-specific exceptional longevity associated with increased GH sensitivity and taller stature 2017 ·Science Advances ·Danny Ben‐Avraham, Diddahally R. Govindaraju, Temuri Budagov, Delphine Fradin, Peter Durda, Bing Liu, (unknown), (unknown), Lital Sharvit, Robert C. Kaplan, Pierre Bougnères, Alex P. Reiner, Alan R. Shuldiner, Pinchas Cohen, Nir Barzilai, Gil Atzmon	46
16	Lipid Metabolism, Abdominal Adiposity, and Cerebral Health in the Amish 2017 ·Obesity ·Meghann C. Ryan, Peter Kochunov, Laura M. Rowland, Braxton D. Mitchell, S. Andrea Wijtenburg, Els Fieremans, Jelle Veraart, Dmitry S. Novikov, Xiaoming Du, Bhim M. Adhikari, (unknown), Heather Bruce, Joshua Chiappelli, Hemalatha Sampath, Seth A. Ament, Jeffrey R. O’Connell, Alan R. Shuldiner, L. Elliot Hong	7
17	A population-specific reference panel empowers genetic studies of Anabaptist populations 2017 ·Scientific Reports ·Liping Hou, Rachel L. Kember, Jared C. Roach, Jeffrey R. O’Connell, David W. Craig, Maja Bućan, William K. Scott, Margaret A. Pericak‐Vance, Jonathan L. Haines, Michael H. Crawford, Alan R. Shuldiner, Francis J. McMahon	9
18	Vitamin and Supplement Use among Old Order Amish: Sex-Specific Prevalence and Associations with Use 2014 ·Journal of the Academy of Nutrition and Dietetics ·Robert M. Reed, (unknown), Patrick F. McArdle, Michael Miller, Toni I. Pollin, Alan R. Shuldiner, Nanette Steinle, Braxton D. Mitchell	10
19	A Common Variant in the Telomerase RNA Component Is Associated with Short Telomere Length 2010 ·PLoS ONE ·Omer T. Njajou, Elizabeth H. Blackburn, Ludmila Pawlikowska, Massimo Mangino, Coleen Damcott, Pui–Yan Kwok, Timothy D. Spector, Anne B. Newman, Tamara B. Harris, Steven R. Cummings, Richard Cawthon, Alan R. Shuldiner, Ana M. Valdes, Wen-Chi Hsueh	29
20	A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection breakdown → 2008 ·Science ·Toni I. Pollin, Coleen Damcott, Haiqing Shen, Sandra Ott, John C. Shelton, Richard B. Horenstein, Wendy S. Post, John C. McLenithan, Lawrence F. Bielak, Patricia A. Peyser, Braxton D. Mitchell, Michael Miller, Jeffrey R. O’Connell, Alan R. Shuldiner	517

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact